Seliciclib (roscovitine or CYC202) is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2 CDK7 and CDK9 which alter the growth phase or state within the cell cycle of treated cells.
This page contains content from the copyrighted Wikipedia article "Seliciclib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
